The global demand for Diabetic Nephropathy Market is presumed to reach the market size of nearly USD 4.97 BN by 2030 from USD 3.31 BN in 2022 with a CAGR of 5.21% under the study period 2023 - 2030.
Diabetic nephropathy (diabetic kidney disease) is a progressive kidney condition that occurs as a complication of diabetes. It is one of the leading causes of end-stage renal disease (ESRD) worldwide. It develops when prolonged high blood sugar levels in individuals with diabetes damage the small blood vessels (glomeruli) in the kidneys. The kidneys' function in filtering waste products and excess fluids from the blood is impaired, leading to the accumulation of waste and fluid in the body.
The rising prevalence of diabetes worldwide is a significant driver, as diabetes is a leading cause of kidney disease, including diabetic nephropathy. Increased awareness of the link between diabetes and kidney complications has led to enhanced screening efforts, enabling early detection and intervention. Technological advancements in diagnostics, such as urine and blood tests, improve the accuracy of diagnosis and monitoring of diabetic nephropathy. Effective diabetes management, including blood glucose control and lifestyle modifications, plays a crucial role in reducing the risk and progression of diabetic nephropathy. Ongoing research and development activities focused on understanding the disease and developing innovative treatments drive the market. Government initiatives and healthcare policies aimed at improving diabetes care and managing complications, along with increasing healthcare expenditure, also contribute to market growth.
The research report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of diabetic nephropathy. The growth and trends of diabetic nephropathy industry provide a holistic approach to this study.
This section of the diabetic nephropathy market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Drug Class
By Distribution Channel
This section covers the regional outlook, which accentuates current and future demand for the Diabetic Nephropathy market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the diabetic nephropathy market include Janssen Pharmaceuticals, Inc (U.S.), AstraZeneca (U.K.), Aurobindo Pharma Limited (India), Teva Pharmaceutical Industries Ltd (Israel), Sanofi (France), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Bayer AG (Germany), Par Pharmaceuticals (U.S.). This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
1 . PREFACE
1.1. Report Description
1.1.1. Objective
1.1.2. Target Audience
1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Market Research Process
1.3.2. Market Research Methodology
2 . EXECUTIVE SUMMARY
2.1. Highlights of Market
2.2. Global Market Snapshot
3 . DIABETIC NEPHROPATHY – INDUSTRY ANALYSIS
3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter’s Five Force Analysis
3.7. Market Attractiveness Analysis
3.7.1 Market Attractiveness Analysis By Drug Class
3.7.2 Market Attractiveness Analysis By Distribution Channel
3.7.3 Market Attractiveness Analysis By Region
4 . VALUE CHAIN ANALYSIS
4.1. Value Chain Analysis
4.2. Raw Material Analysis
4.2.1. List of Raw Materials
4.2.2. Raw Material Manufactures List
4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
4.4.1. Direct Marketing
4.4.2. Indirect Marketing
4.4.3. Marketing Channel Development Trend
5 . GLOBAL DIABETIC NEPHROPATHY MARKET ANALYSIS BY DRUG CLASS
5.1 Overview by Drug Class
5.2 Historical and Forecast Data
5.3 Analysis by Drug Class
5.4 Angiotensin Converting Enzyme (ACE) Inhibitors Historic and Forecast Sales by Regions
5.5 Angiotensin Receptor Blockers Historic and Forecast Sales by Regions
5.6 Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Historic and Forecast Sales by Regions
5.7 Mineralocorticoid Receptor Antagonists Historic and Forecast Sales by Regions
5.8 Others Historic and Forecast Sales by Regions
6 . GLOBAL DIABETIC NEPHROPATHY MARKET ANALYSIS BY DISTRIBUTION CHANNEL
6.1 Overview by Distribution Channel
6.2 Historical and Forecast Data
6.3 Analysis by ...